AU6739398A - Vp22 proteins and uses thereof - Google Patents

Vp22 proteins and uses thereof

Info

Publication number
AU6739398A
AU6739398A AU67393/98A AU6739398A AU6739398A AU 6739398 A AU6739398 A AU 6739398A AU 67393/98 A AU67393/98 A AU 67393/98A AU 6739398 A AU6739398 A AU 6739398A AU 6739398 A AU6739398 A AU 6739398A
Authority
AU
Australia
Prior art keywords
protein
cell
cells
derivative
microtubules
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU67393/98A
Other languages
English (en)
Inventor
Gillian Daphne Elliott
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Phogen Ltd
Original Assignee
Phogen Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Phogen Ltd filed Critical Phogen Ltd
Publication of AU6739398A publication Critical patent/AU6739398A/en
Priority to AU87314/01A priority Critical patent/AU783081B2/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16622—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
AU67393/98A 1997-03-21 1998-03-23 Vp22 proteins and uses thereof Abandoned AU6739398A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU87314/01A AU783081B2 (en) 1997-03-21 2001-11-05 VP22 proteins and uses thereof

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9705903.4A GB9705903D0 (en) 1997-03-21 1997-03-21 VP22 Proteins and uses thereof
GB9705903 1997-03-21
PCT/GB1998/000873 WO1998042742A1 (en) 1997-03-21 1998-03-23 Vp22 proteins and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU87314/01A Division AU783081B2 (en) 1997-03-21 2001-11-05 VP22 proteins and uses thereof

Publications (1)

Publication Number Publication Date
AU6739398A true AU6739398A (en) 1998-10-20

Family

ID=10809645

Family Applications (1)

Application Number Title Priority Date Filing Date
AU67393/98A Abandoned AU6739398A (en) 1997-03-21 1998-03-23 Vp22 proteins and uses thereof

Country Status (7)

Country Link
US (2) US20020128174A1 (https=)
EP (1) EP0971953A1 (https=)
JP (1) JP2001520521A (https=)
AU (1) AU6739398A (https=)
CA (1) CA2283794A1 (https=)
GB (1) GB9705903D0 (https=)
WO (1) WO1998042742A1 (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6423334B1 (en) 1997-10-01 2002-07-23 Elan Corporation, Plc Composition and method for enhancing transport across gastrointestinal tract cell layers
GB9816761D0 (en) 1998-07-31 1998-09-30 Phogen Limited Herpesvirus preparations and their uses
DE60040274D1 (de) * 1999-03-10 2008-10-30 Phogen Ltd Verabreichung von nukleinsäuren und proteinen an zellen
US6358739B1 (en) 1999-04-12 2002-03-19 Modex Therapeutiques, S.A. Transiently immortalized cells
US6451601B1 (en) 1999-04-12 2002-09-17 Modex Therapeutiques, S.A. Transiently immortalized cells for use in gene therapy
GB9930519D0 (en) * 1999-12-24 2000-02-16 Phogen Limited Uses of transport proteins
US6688084B2 (en) * 2000-03-24 2004-02-10 International Paper Company Automated bulk box strapper
BRPI0406647A (pt) * 2003-01-06 2005-12-06 Angiochem Inc Método para transportar um composto através da barreira sanguìnea do cérebro
US9365634B2 (en) * 2007-05-29 2016-06-14 Angiochem Inc. Aprotinin-like polypeptides for delivering agents conjugated thereto to tissues
TR201905480T4 (tr) 2008-04-18 2019-05-21 Angiochem Inc Paklitaksel, paklitaksel analogları veya paklitaksel konjugatlarının farmasötik bileşimleri ve ilgili preparasyon ve kullanım yöntemleri.
MX2011004019A (es) 2008-10-15 2011-06-24 Angiochem Inc Conjugados de etoposido y doxorubicina para entrega de farmacos.
BRPI0920209A2 (pt) 2008-10-15 2015-12-22 Angiochem Inc conjugados de agonistas de glp-1 e usos dos mesmos
CA2745524C (en) 2008-12-05 2020-06-09 Angiochem Inc. Conjugates of neurotensin or neurotensin analogs and uses thereof
WO2010069074A1 (en) 2008-12-17 2010-06-24 Universite Du Quebec A Montreal Membrane type-1 matrix metalloprotein inhibitors and uses thereof
WO2010121379A1 (en) 2009-04-20 2010-10-28 Angiochem Inc Treatment of ovarian cancer using an anticancer agent conjugated to an angiopep-2 analog
AU2010268726A1 (en) 2009-07-02 2012-01-19 Angiochem Inc. Multimeric peptide conjugates and uses thereof
DK3307326T3 (da) 2015-06-15 2020-10-19 Angiochem Inc Fremgangsmåder til behandling af leptomeningeal karcinomatose

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4942184A (en) 1988-03-07 1990-07-17 The United States Of America As Represented By The Department Of Health And Human Services Water soluble, antineoplastic derivatives of taxol
US4960790A (en) 1989-03-09 1990-10-02 University Of Kansas Derivatives of taxol, pharmaceutical compositions thereof and methods for the preparation thereof
US5278324A (en) 1990-08-28 1994-01-11 Virginia Tech Intellectual Properties, Inc. Water soluble derivatives of taxol
US5059699A (en) 1990-08-28 1991-10-22 Virginia Tech Intellectual Properties, Inc. Water soluble derivatives of taxol
TW223634B (https=) 1991-03-18 1994-05-11 Kingston David G I
FR2679230B1 (fr) 1991-07-16 1993-11-19 Rhone Poulenc Rorer Sa Nouveaux derives d'analogues du taxol, leur preparation et les compositions qui les contiennent.
CA2128693A1 (en) 1992-01-31 1993-08-05 Peter B. Schiff Taxol as a radiation sensitizer
US5272171A (en) 1992-02-13 1993-12-21 Bristol-Myers Squibb Company Phosphonooxy and carbonate derivatives of taxol
CA2086874E (en) 1992-08-03 2000-01-04 Renzo Mauro Canetta Methods for administration of taxol
US5631278A (en) 1992-12-02 1997-05-20 Thomas Jefferson University Methods of killing protozoal parasites
US5356927A (en) 1992-12-02 1994-10-18 Thomas Jefferson University Methods of treating plasmodium and babesia parasitic infections
US5583153A (en) * 1994-10-06 1996-12-10 Regents Of The University Of California Use of taxol in the treatment of rheumatoid arthritis
BR9610058A (pt) * 1995-07-28 1999-07-27 Marie Curie Cancer Care Uso de vp22 ou uma porção ativa fragmento ou homólogo do mesmo proteína de transporte ácido nucleíco vetor de expressão célula hospedeira de mamíferos ou microbiana e processos para transportar uma proteína ou peptídeo desejado para uma população de marcaç o de células e para transportar uma molécula desejada em uma população de células
US6017735A (en) * 1997-01-23 2000-01-25 Marie Curie Cancer Care Materials and methods for intracellular transport and their uses

Also Published As

Publication number Publication date
US7067632B2 (en) 2006-06-27
JP2001520521A (ja) 2001-10-30
US20020128174A1 (en) 2002-09-12
EP0971953A1 (en) 2000-01-19
US20050118717A1 (en) 2005-06-02
CA2283794A1 (en) 1998-10-01
GB9705903D0 (en) 1997-05-07
WO1998042742A1 (en) 1998-10-01

Similar Documents

Publication Publication Date Title
US7067632B2 (en) VP22 proteins and uses thereof
US20250082778A1 (en) Rna guided eradication of human jc virus and other polyomaviruses
JP5284780B2 (ja) 癌の治療のための単純ヘルペスウイルス２型変異体の使用
RU2146149C1 (ru) Способ и композиции, содержащие dna-поражающие агенты и р53
AU705563B2 (en) Transport proteins and their uses
JP2019512458A (ja) Ｒｎａによって誘導された、ヒトｊｃウイルス及び他のポリオーマウイルスの根絶
JP2001508304A (ja) 細胞内及び細胞間輸送のための融合タンパク質、並びにその使用
CA2600370A1 (en) Bioactive fus1 peptides and nanoparticle-polypeptide complexes
WO1998056938A1 (en) Lipoproteins as nucleic acid vectors
CN1816564B (zh) 能选择性杀伤癌细胞的RasGAP衍生肽
LaVail et al. Viral regulation of the long distance axonal transport of herpes simplex virus nucleocapsid
AU776817B2 (en) Uses of transport proteins for controlling cell cycle
Lee et al. Gene delivery using a receptor‐mediated gene transfer system targeted to hepatocellular carcinoma cells
EP1549339B1 (en) Targeting of herpes simplex virus to specific receptors
US20060210536A1 (en) Methods and compositions for inhibiting stat signaling pathways
AU783081B2 (en) VP22 proteins and uses thereof
US8765666B2 (en) Adenovirus dodecahedron particles for delivery of pharmaceutical agents
CA2379171A1 (en) Methods for treatment of hyperproliferative diseases using human mda-7
MXPA99008620A (en) Vp22 proteins and uses thereof
WO2001090159A2 (en) Compositions and methods for delivery of a molecule into a cell
Zavaglia et al. Poor intercellular transport and absence of enhanced antiproliferative activity after non‐viral gene transfer of VP22‐P53 or P53‐VP22 fusions into p53 null cell lines in vitro or in vivo
US5847083A (en) Modified p53 constructs which enhance DNA binding
US20060193832A1 (en) Use of the sodium iodine symporter to effect uptake of iodine
US20250066420A1 (en) Pd-l1 inhibitory peptide for cancer immunotherapy
AU770157B2 (en) Use of semaphorin for modulation of cellular efflux

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted